Cost-utility of secukinumab in Italian patients with moderate to severe plaque-type psoriasis

Abstract

SummaryIntroduction. Chronic plaque-type psoriasis is diagnosed in about 1,350,000 patients in Italy. About 20-30% of them suffers from moderate/ severe condition which adversely affects quality of life. The objective of this study was to examine the cost-utility of secukinumab 300 mg vs other systemic biologic drugs and standard of care (SoCcyclosporine and methotrexate) from the Italian National Health System (INHS) perspective. Methods. A 10-year cost-utility model, previously developed, was adapted to INHS. The model considers clinical benefits, resource consumption, and costs related to secukinumab use in moderate/severe plaque-type psoriasis treatment compared with available alternatives in Italy. Clinical data and utility scores were derived from secukinumab trials and published evidence. Only direct costs were taken into account; both benefits and costs were discounted at 3%. Univariate sensitivity analyses (i.e. 5-year time horizon and price of biosimilar infliximab) were performed to test the results robustness. Results. Secukinumab was dominant vs infliximab